Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NKTR

DatePrice TargetRatingAnalyst
3/14/2025$6.00Perform → Outperform
Oppenheimer
1/8/2025$4.00Buy
B. Riley Securities
12/10/2024$6.50Buy
H.C. Wainwright
11/4/2024$7.00Overweight
Piper Sandler
9/30/2024$4.00Buy
BTIG Research
6/28/2024$2.00Buy
Rodman & Renshaw
11/20/2023Underweight
JP Morgan
11/9/2023Market Perform → Outperform
TD Cowen
More analyst ratings

$NKTR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

    SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time – webcast link hereThe fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-pres

    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

    SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "The significant progress we made last year in advancing our immunology pipeline positions us for two value-creating data milestones in 20

    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, March 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar w

    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$NKTR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$NKTR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$NKTR
SEC Filings

See more

$NKTR
Leadership Updates

Live Leadership Updates

See more
  • DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

    Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

    $DMAC
    $MRNS
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BigHat Biosciences Appoints Rob Chess, Serial Entrepreneur, to its Board of Directors

    BigHat Biosciences, a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat's board of directors. Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies. "We look forward to leveraging Rob's deep expertise in drug discovery and development to accelerate our work creating better antibody therapies for patients," said Mark DePristo, PhD., BigHat's CEO and

    $NKTR
    $TWST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D.

    SAN FRANCISCO, Nov. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced it has appointed Diana M. Brainard, M.D., as an independent director to its Board of Directors. Dr. Brainard brings over two decades of experience working in the healthcare sector and academia to Nektar. She currently serves as Chief Executive Officer (CEO) of AlloVir, Inc., a leading late clinical stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. "We are very ple

    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$NKTR
Financials

Live finance-specific insights

See more
  • Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

    SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "The significant progress we made last year in advancing our immunology pipeline positions us for two value-creating data milestones in 20

    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, March 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar w

    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

    SAN FRANCISCO, Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST / 12:00 p.m. PST. Nektar's Chief Research & Development Officer, Jonathan Zalevsky, Ph.D., will be hosting the webcasted event. He will be joined by leading Diabetes experts, including: Dr. Kevin Herold, TrialNet Chair and C.N.H. Long Professor of Immunobiology and Medicine at Yale University at Yale School of Medicine;Dr. Megan Levings, Professor, D

    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$NKTR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more